progressed infections us liver Good development Carol. joining you programs for our of At treat third the and end to viral thank you, afternoon, Enanta’s have clinical everyone, diseases fiscal Thank well. today. quarter and
clinical Our track of three which pipeline designation. studies have we is maturing different and have fast with ongoing compounds, all
data significant line lead EDP-XXX, most HBV Our top Phase a our and highly recent achievements were candidate for our statistically announcement of study of RSV the X initiation the program. of from
HCV X, weeks genotype treatment with partner AbbVie XX infection. and to X, MAVIRET, Commission granted to has our from X addition, for treatment-naïve, weeks cirrhosis X, In in compensated European we once-daily shorten marketing AbbVie recently X, chronic X announced the or HCV patients that and to authorization duration
[Audio for and program, I’ll begin an announced of clinical known yielded exciting In milestone the this most a as most our challenge RSV. of from programs for Enanta promising June, advanced development we study. successful trial my was Gap] completion very data syncytial our respiratory EDP-XXX virus of with review some RSV
EDP-XXX reduction study highly compared this statistically of X.XXX. is viral from remember significant clinical a the achieved load demonstrated statistically And that data than means placebo. p-value in highly Specifically that to that less significant and in symptoms resolution both
live The previously now viral copies based quantitative of number load cell that data the in treatment statistically data namely have was result additional virus. also based to in RT-PCR This reduction the virus from we cell on group. both live placebo using across significant. highly show RNA reported, consistent we viral groups The an data with subjects infectivity XX% approximately of is assays compared RSV from the
the drugs, for In above pharmacokinetics, mean the vitro demonstrated times of levels XX just drug good next times cells. the approximately RSV to addition, and namely XX dose infected human were of trough plasma at maintained EDP-XXX levels ECXX before in
comparable was This and means favorable reduce the higher Overall than days dosing through placebo and cells. amount of profile day were EDP-XXX of infected RNA that viral RSV was tolerated to over drug of the levels safety needed to follow-up. of dramatically the achieved XX% generally a humans that demonstrated drug well XX in five
There drug. study of and were adverse no serious no events discontinuations
of additional the study We upcoming in challenge conference. details present an expect to
of the halt of shown trough has get the that effectively the progression that with In and levels to safely drug summary, infection challenge study high infection. site can deliver blood concentrations we target
has very well subjects EDP-XXX has tolerated, generally XXX over have demonstrated up the to seven profile for exposed Also similar and to safety been favorable now placebo. days to drug been
We are very profile. pleased safety this with
replication Because for we inhibitors EDP-XXX from into RSV further a is in viral confidence time currently us and differentiated in process resistance trials particularly and fusion study’s have vitro. known safety excellent the EDP-XXX to high-barrier has Challenge of efficacy some development. EDP-XXX since give that directly data to demonstrated targets advance
can now to RSV infection. community outpatients adult in acquired that with EDP-XXX demonstrate efficacy show We aim
goal we then initiate conducting populations. Our is study pediatric anticipate than studies additional before of in at-risk patients and to XXXX our other Xb the calendar end first Phase
Enrollment – study is Let’s study move ARGON-X, study quarter. NASH lead for we top safety, designed data next line the to the NASH of most program, efficacy for and is agonist Phase and XX-week now evaluate our randomized been pharmacokinetics and anticipate complete advanced to of in is the FXR double-blind placebo-controlled one EDP-XXX, sharing for a tolerability, this two NASH ongoing our one NASH. our most in which by end EDP-XXX. has studies, investigated PBC. X
want to criteria. improvements ALT, and CX, we see other in positive among Directionally, FGFXX
combination to Assuming both preferred. the This would assets first look data to in EDP-XXX explore, on Phase time of and calendar a the which we and gain data be asset initiate partner partners quarter to plan the prior X. to will us to and study supported, Xb aggregate allow more Phase XXXX
believe to today continue most promising FXR in development that of We NASH. one is mechanisms for the
to year. we addition to from follow-on a our made expect In announce with development EDP-XXX, progress program candidate which good we��ve later this
study the PBC, patients to we who INTREPID EDP-XXX continue enroll the updates proceeds. further will in Regarding study as provide of
mechanisms Beyond research NASH. continue FXR, for we other also our into
study X HBV. study X double-blind shift is Phase clinical HBV Part our Let’s designed randomized evaluate core Xa, to Class inhibitor EDP-XXX. with Xb a placebo-controlled the is this to initiated novel activity of We in will pharmacokinetics tolerability while doses multiple X infection. subjects, doses NUC-suppressed EDP-XXX HBV Part single antiviral of patients healthy the with safety, chronic and EDP-XXX in ascending explore ascending of and recently
portion the first share and to in the once-daily. enroll to volunteer healthy study, initiate Part A EDP-XXX X We cohorts to orally administered up XXXX. and data steady evaluate plan of to HBV calendar NUC-suppressed plan from subjects quarter dose patients six of with is dosing XX approximately the
this are In viremic and to chronic patients we initiate B currently HBV study Xb Phase not in treatment. addition, patients planning on hepatitis another time
novo our our are hepatocytes antiviral by the that that excitement EDP-XXX this during formation And demonstrated of replication HBV series de is a for early HBV of cccDNA the data of compounds mechanism. potent Preclinical support selected primary HBV from new characterized when human in activity. was potent and given inhibitor infection. EDP-XXX data preclinical our lead prevents promising
In is EDP-XXX X show are transcriptase inhibitors, combinations current therapies inhibitor that resulting EDP-XXX reverse pan-genotypic additive core with data synergistic nucleoside which that for and the also Class antiviral of with to vitro or a in antiviral effects. HBV
greater X EDP-XXX inhibitor reduction the In infected mechanism. of we vivo viral efficacy core may load HBV potential EDP-XXX mice. on excellent PXB our demonstrated for Based preclinical with believe than data, best-in-class models in have log
we all on our clinical to communicating starting our this on my look NASH And by and I’d with this remarks programs progress to conclude the you like forward other Phase later then by X updates our programs year. of ARGON-X quarter additional end reminding that data
here stop the call the Paul? and over quarter. financials for I’ll to turn to Paul discuss our